429 filings
Page 16 of 22
8-K
pa5bvlm4
26 May 17
Departure of Directors or Certain Officers
12:00am
8-K
8h7tiws7
4 May 17
Other Events
12:00am
8-K
8brt32129pe
2 May 17
Contravir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
12:00am
8-K
hyvei 82g
25 Apr 17
ContraVir Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
12:00am
424B5
0iamtz33vylt vl5
25 Apr 17
Prospectus supplement for primary offering
12:00am
8-K
krfksx
24 Apr 17
Data Enhances Understanding of ContraVir’s Complementary Anti-HBV
12:00am
424B5
2vg6uowto ndlbvl
24 Apr 17
Prospectus supplement for primary offering
12:00am
8-K
c797vzjrswfzi 6wy2
20 Apr 17
Oral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients
12:00am
8-K
fd1sa7 xzpsnb7g8i
4 Apr 17
Other Events
12:00am
S-8
8siv 39cqh
23 Jan 17
Registration of securities for employees
12:00am
8-K
upzgawpg9 rrp9iurgw
4 Jan 17
ContraVir Pharmaceuticals to Present at Biotech Showcase 2017
12:00am
8-K
vrc23pl1
3 Jan 17
ContraVir Awarded Grant from Canada’s National Research Council to Advance CRV431 for the Treatment of Hepatitis B
12:00am
8-K
p5a8u6 ibzp6o
19 Dec 16
Other Events
12:00am
8-K
re0v8m
15 Dec 16
ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
12:00am
8-K
soc7hklztjby 6ty9o19
9 Dec 16
Other Events
12:00am
8-K
j7rvs0njpd4i 1t3
7 Nov 16
ContraVir to Present at AASLD’s The Liver Meeting® 2016
12:00am
DEFA14A
iv0et7hhn4bp
31 Oct 16
Additional proxy soliciting materials
12:00am